Evidence map›Paper›PMID 24312374›Full record

ArticlePloS one2013

Profiling inflammatory responses with microfluidic immunoblotting.

Huai-Ning Chang, Pascale R Leroueil, Katherine Selwa, C J Gasper, Ryan E Tsuchida, Jason J Wang, Walker M McHugh, Timothy T Cornell, James R Baker, Sascha N Goonewardena

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03829046 (The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03829046 phase4completedstarted 2019, after this paper: background citation

The Effects of Evolocumab on Endothelial and Inflammatory Biocellular Markers in Patients With Diabetes and Atherosclerotic Vascular Disease (METCHNIKOFF)

Ran2019Enrolled41Registered outcomes11Posted comparisons0ConditionsAtherosclerotic Vascular Disease, Microvascular Dysfunction, Type2 DiabetesArmsEvolocumab, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Biomarkers in pediatric acute respiratory distress syndrome.Annals of translational medicine · 2019
    Review
  4. Recent Advances in Microscale Western Blotting.Analytical methods : advancing methods and applications · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huai-Ning ChangMichigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan, Ann Arbor, Michigan, United States of America.
Pascale R Leroueil
Katherine Selwa
C J Gasper
Ryan E Tsuchida
Jason J Wang
Walker M McHugh
Timothy T Cornell
James R Baker
Sascha N Goonewardena

Funding

MKP-2 as an Endogenous Regulator of the Pro-Inflammatory Response in SepsisK08HD062142 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CORNELL, TIMOTHY T · 2010 to 2013
$505k
NICHD NIH HHS K08 HD062142
6 · The paper itself

Abstract

Rapid profiling of signaling pathways has been a long sought after goal in biological sciences and clinical medicine. To understand these signaling pathways, their protein components must be profiled. The protein components of signaling pathways are typically profiled with protein immunoblotting. Protein immunoblotting is a powerful technique but has several limitations including the large sample requirements, high amounts of antibody, and limitations in assay throughput. To overcome some of these limitations, we have designed a microfluidic protein immunoblotting device to profile multiple signaling pathways simultaneously. We show the utility of this approach by profiling inflammatory signaling pathways (NFκB, JAK-STAT, and MAPK) in cell models and human samples. The microfluidic immunoblotting device can profile proteins and protein modifications with 5380-fold less antibody compared to traditional protein immunoblotting. Additionally, this microfluidic device interfaces with commonly available immunoblotting equipment, has the ability to multiplex, and is compatible with several protein detection methodologies. We anticipate that this microfluidic device will complement existing techniques and is well suited for life science applications.

Indexed as

AnimalsBlotting, WesternCell LineHumansInflammationMiceMicrofluidicsProteinsProteins

Identifiers

PMID24312374
PMCPMC3842271

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.